G1 Therapeutics Chief Business Officer Mark Avagliano receives $5.5M in 2019
G1 Therapeutics reports 2019 executive compensation
By ExecPay News
Published: April 24, 2020
G1 Therapeutics reported fiscal year 2019 executive compensation information on April 24, 2020.
In 2019, six executives at G1 Therapeutics received on average a compensation package of $2.5M, a 22% decrease compared to previous year.
Average pay of disclosed executives at G1 Therapeutics
Mark Avagliano, Chief Business Officer, received $5.5M in total. 93% of Avagliano's compensation, or $5.1M, was in option awards. Avagliano also received $143K in non-equity incentive plan, $182K in salary, as well as $53K in other compensation.
For fiscal year 2019, the median employee pay was $213,060 at G1 Therapeutics. Therefore, the ratio of Mark Avagliano's pay to the median employee pay was 26 to one.
Mark A. Velleca, Chief Executive Officer, received a compensation package of $4M, which increased by 108% compared to previous year. 78% of the compensation package, or $3.1M, was in option awards.
Jennifer K. Moses, Chief Financial Officer, earned $1.4M in 2019.
Rajesh K. Malik, Chief Medical Officer, received $1.4M in 2019, which increases by 9% compared to 2018.
John Demaree, Chief Commercial Officer, earned $1.3M in 2019, a 82% decrease compared to previous year.
Barclay Buck A. Phillips, Chief Financial Officer, received $1.2M in 2019, which increases by 70% compared to 2018.
Related executives
Mark Velleca
G1 Therapeutics
Chief Executive Officer
Jennifer Moses
G1 Therapeutics
Chief Financial Officer
Mark Avagliano
G1 Therapeutics
Chief Business Officer
Rajesh Malik
G1 Therapeutics
Chief Medical Officer
John Demaree
G1 Therapeutics
Chief Commercial Officer
Barclay Phillips
G1 Therapeutics
Chief Financial Officer
You may also like
Source: SEC filing on April 24, 2020.